Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
BioNTech SE
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Bristol-Myers Squibb
Eli Lilly and Company
Pheon Therapeutics
AstraZeneca
National Institutes of Health Clinical Center (CC)
Pfizer
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
Instil Bio
M.D. Anderson Cancer Center
AstraZeneca
BeOne Medicines
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Exelixis
BeOne Medicines
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
Amgen
Institut Claudius Regaud
National Institutes of Health Clinical Center (CC)
Vastra Gotaland Region
BioNTech SE
Kura Oncology, Inc.
Boehringer Ingelheim
Boehringer Ingelheim
Zymeworks BC Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
AstraZeneca
AbbVie
National Cancer Institute (NCI)
RayzeBio, Inc.
Johnson & Johnson Enterprise Innovation Inc.
Eli Lilly and Company
Iambic Therapeutics, Inc
Amgen
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)